See more : 26 Capital Acquisition Corp. (ADER) Income Statement Analysis – Financial Results
Complete financial analysis of Frequency Therapeutics, Inc. (FREQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Frequency Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Empress Royalty Corp. (EMPR.V) Income Statement Analysis – Financial Results
- Parsec Capital Acquisitions Corp (PCXCU) Income Statement Analysis – Financial Results
- Cholamandalam Investment and Finance Company Limited (CHOLAFIN.NS) Income Statement Analysis – Financial Results
- Siyata Mobile Inc. (SYTA) Income Statement Analysis – Financial Results
- Tamilnad Mercantile Bank Limited (TMB.BO) Income Statement Analysis – Financial Results
Frequency Therapeutics, Inc. (FREQ)
About Frequency Therapeutics, Inc.
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 14.07M | 36.98M | 28.95M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 14.07M | 36.98M | 28.95M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 49.42M | 60.92M | 37.42M | 18.78M | 11.88M | 11.97M |
| General & Administrative | 33.58M | 37.18M | 27.12M | 30.84M | 7.06M | 4.34M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.58M | 37.18M | 27.12M | 30.84M | 7.06M | 4.34M |
| Other Expenses | 1.06M | -266.00K | 0.00 | 16.00M | 0.00 | 0.00 |
| Operating Expenses | 83.00M | 98.10M | 64.53M | 49.62M | 18.94M | 16.31M |
| Cost & Expenses | 83.00M | 98.10M | 64.53M | 49.62M | 18.94M | 16.31M |
| Interest Income | 1.33M | 397.00K | 994.00K | 1.78M | 0.00 | -174.00K |
| Interest Expense | 961.00K | 764.00K | 0.00 | 1.78M | 106.00K | 174.00K |
| Depreciation & Amortization | 2.38M | 2.91M | -80.00K | -145.00K | 654.00K | 531.00K |
| EBITDA | -80.62M | -81.13M | -27.55M | -20.68M | -18.29M | -12.02M |
| EBITDA Ratio | 0.00% | -576.66% | -74.71% | -71.92% | 0.00% | 0.00% |
| Operating Income | -83.00M | -84.03M | -27.55M | -20.68M | -18.94M | -16.31M |
| Operating Income Ratio | 0.00% | -597.32% | -74.49% | -71.42% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.42M | -640.00K | 1.07M | 1.93M | -224.00K | -3.93M |
| Income Before Tax | -81.58M | -84.67M | -26.48M | -18.75M | -19.17M | -20.24M |
| Income Before Tax Ratio | 0.00% | -601.87% | -71.59% | -64.76% | 0.00% | 0.00% |
| Income Tax Expense | -2.00K | 15.00K | 35.00K | -2.74M | -118.00K | 3.93M |
| Net Income | -81.58M | -84.69M | -26.51M | -16.00M | -19.17M | -20.24M |
| Net Income Ratio | 0.00% | -601.98% | -71.68% | -55.29% | 0.00% | 0.00% |
| EPS | -2.33 | -2.47 | -0.82 | -1.85 | -1.59 | -1.68 |
| EPS Diluted | -2.33 | -2.47 | -0.82 | -1.85 | -1.59 | -1.68 |
| Weighted Avg Shares Out | 35.08M | 34.35M | 32.25M | 8.65M | 12.06M | 12.06M |
| Weighted Avg Shares Out (Dil) | 35.08M | 34.35M | 32.25M | 8.65M | 12.06M | 12.06M |
FREQ Stock: Berger Montague Reminds Investors of Upcoming Deadline for Securities Fraud Class Action Against Frequency Therapeutics, Inc. (FREQ); Lead Plaintiff Deadline is August 2, 2021
Philadelphia, Pennsylvania--(Newsfile Corp. - July 27, 2021) - Berger Montague reminds investors of the upcoming deadline of August 2, 2021 for investors to seek lead plaintiff status in a securities fraud class action against Frequency Therapeutics, Inc. ("Frequency" or the...
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - July 27, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) for violations of §§10(b)...
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - July 27, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) for violations of §§10(b)...
ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Frequency Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - FREQ
NEW YORK, July 26, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021, inclusive (the "Class Period"),...
UPCOMING DEADLINE: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit - FREQ
San Diego, California--(Newsfile Corp. - July 26, 2021) - The Frequency Therapeutics, Inc. (NASDAQ: FREQ) class action lawsuit charges Frequency Therapeutics and its CEO with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers of Frequency...
UPCOMING DEADLINE: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit - FREQ
San Diego, California--(Newsfile Corp. - July 26, 2021) - The Frequency Therapeutics, Inc. (NASDAQ: FREQ) class action lawsuit charges Frequency Therapeutics and its CEO with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers of Frequency...
FREQ ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 2, 2021 in the Class Action Filed on Behalf of Frequency Therapeutics, Inc. Limited Shareholders
New York, New York--(Newsfile Corp. - July 26, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Frequency Therapeutics, Inc. (NASDAQ: FREQ) alleging that the Company violated federal securities...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Frequency Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 2, 2021 - FREQ
New York, New York--(Newsfile Corp. - July 26, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Frequency Therapeutics, Inc. ("Frequency Therapeutics") (NASDAQ: FREQ) between...
Berger Montague Reminds Investors of Upcoming Deadline for Securities Fraud Class Action Against Frequency Therapeutics, Inc. (FREQ); Lead Plaintiff Deadline is August 2, 2021
Philadelphia, Pennsylvania--(Newsfile Corp. - July 26, 2021) - Berger Montague reminds investors of the upcoming deadline of August 2, 2021 for investors to seek lead plaintiff status in a securities fraud class action against Frequency Therapeutics, Inc. ("Frequency" or the...
Berger Montague Reminds Investors of Upcoming Deadline for Securities Fraud Class Action Against Frequency Therapeutics, Inc. (FREQ); Lead Plaintiff Deadline is August 2, 2021
Philadelphia, Pennsylvania--(Newsfile Corp. - July 26, 2021) - Berger Montague reminds investors of the upcoming deadline of August 2, 2021 for investors to seek lead plaintiff status in a securities fraud class action against Frequency Therapeutics, Inc. ("Frequency" or the...
Source: https://incomestatements.info
Category: Stock Reports